ISLAMABAD: Pakistan and China have further enhanced collaboration in pharmaceutical sector, by launching Basagine Pen, a pre-filled insulin.
The insulin was co-developed by Pakistan Getz Pharma and China Gan&Lee Pharmaceuticals.
This marks a further development in the pharmaceutical collaboration between China and Pakistan, Gwadar Pro reported.
The milestone lunching-event was attended by Khalid Mahmood, CEO and Managing Director of Getz Pharma, and Du Kai, CEO of Gan&Lee Pharmaceuticals.
“Getz Pharma has been a trusted overseas partner of our company for over a decade, with previous collaborations involving raw materials of second-generation and third-generation insulin.
The launch of the Basagine Pen will further enhance our product portfolio in diabetes treatment, leveraging the strengths of both companies.”
Du Kai highlighted the long-standing partnership between the two companies.
According to data from the International Diabetes Federation (IDF), Pakistan has approximately 33 million diabetes patients aged 20 to 79, with an annual average expenditure of USD80.1 per patient.
The prevalence of diabetes among adults aged 20 to 79 in Pakistan stands at 30.8%.
Unfortunately, many diabetes patients in the country do not have access to timely and adequate medication.
“The introduction of the Basagine Pen holds the promise of improving this situation by providing higher-quality and more accessible medication options for local patients,” emphasized the representative from Getz Pharma.
The collaboration between Gan&Lee Pharmaceuticals and Getz Pharma brings together China’s advanced pharmaceutical technology and manufacturing capabilities with Pakistan’s understanding of the local market and distribution networks.
This synergy allows for the development and availability of innovative treatment options for diabetes patients in Pakistan.
